Found: 11
Select item for more details and to access through your institution.
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation-results for Canada, Italy, Sweden and Switzerland.
- Published in:
- European Journal of Health Economics, 2013, v. 14, n. 3, p. 481, doi. 10.1007/s10198-012-0391-x
- By:
- Publication type:
- Article
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 2107, doi. 10.1007/s13555-023-00965-5
- By:
- Publication type:
- Article
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults.
- Published in:
- Dermatology & Therapy, 2017, v. 7, n. 4, p. 493, doi. 10.1007/s13555-017-0201-6
- By:
- Publication type:
- Article
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
- Published in:
- Journal of Neurology, 2013, v. 260, n. 10, p. 2472, doi. 10.1007/s00415-013-6979-y
- By:
- Publication type:
- Article
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 3, p. 469, doi. 10.1007/s40257-022-00754-4
- By:
- Publication type:
- Article
682 - Dupilumab demonstrates higher likelihood of maintaining efficacy outcomes compared with lebrikizumab in monotherapy at week 52: results from a placebo-adjusted indirect comparison analysis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.056
- By:
- Publication type:
- Article
Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii9, doi. 10.1093/bjd/ljad498.011
- By:
- Publication type:
- Article
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
- Published in:
- Acta Dermato-Venereologica, 2021, v. 101, n. 11, p. 1, doi. 10.2340/actadv.v101.307
- By:
- Publication type:
- Article
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.
- Published in:
- Acta Dermato-Venereologica, 2021, v. 101, n. 7, p. 1, doi. 10.2340/00015555-3848
- By:
- Publication type:
- Article